EU steers clear of Aduhelm as a bigger headache threatens

Biogen’s Aduhelm has quickly become the most controversial drug of recent years, and today’s news from the CHMP shows the EU regulator wanting no part of the drama. The agency’s negative trend vote sets up the Alzheimer’s drug to be rejected formally next month.

Many will shrug and ask, so what? It is true that EU was never going to be a big market for Aduhelm, but for Biogen the bad news keeps on coming. Monday saw the shock departure of Al Sandrock, the exec who had done more than most to champion Aduhelm, and next up is a US coverage decision that could invigorate – or completely stall – the drug’s sales.